Point Biopharma Stock Nearly Doubles On Eli Lilly Deal

Eli Lilly is spending $1.4 billion on buying Point Biopharma Global Inc. Point Biopharma is a radiopharmaceutical company focused on cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.